A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
Latest Information Update: 21 Apr 2026
At a glance
- Drugs Crinecerfont (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
Most Recent Events
- 21 Apr 2026 New trial record